FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Cormack Scott Daniel
   2. Issuer Name and Ticker or Trading Symbol
ONCOGENEX PHARMACEUTICALS, INC. [OGXI] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President and CEO
(Last)
(First)
(Middle)
400-1001 W. BROADWAY		 3. Date of Earliest Transaction (Month/Day/Year)
03/14/2016
(Street)

VANCOUVER, A1 V6H 4B1		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/14/2016   M   25,000 (1) A $ 0 136,942 D  
Common Stock 03/15/2016   S   12,033 (2) D $ 0.83 124,909 D  
Common Stock               68,743 I By Spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (RSU) (3) 03/14/2016   M     4,687   (4) 04/13/2016 Common Stock 4,687 $ 0 0 D  
Restricted Stock Unit (RSU) (3) 03/14/2016   M     4,688   (5) 01/31/2017 Common Stock 4,688 $ 0 4,687 D  
Restricted Stock Unit (RSU) (3) 03/14/2016   M     6,250   (6) 04/13/2018 Common Stock 6,250 $ 0 12,500 D  
Restricted Stock Unit (RSU) (3) 03/14/2016   M     9,375   (7) 06/18/2019 Common Stock 9,375 $ 0 28,125 D  
Stock Option (right to buy) $ 0.85 03/14/2016   A   300,000     (8) 03/14/2026 Common Stock 300,000 $ 0 300,000 D  
Stock Option (right to buy) $ 7.25               (9) 05/12/2016 Common Stock 4,130   4,130 I By Spouse
Stock Option (right to buy) $ 14.2               (10) 06/08/2020 Common Stock 1,750   1,750 I By Spouse
Stock Option (right to buy) $ 16.83               (11) 01/03/2021 Common Stock 28,820   28,820 I By Spouse
Stock Option (right to buy) $ 13               (12) 05/08/2022 Common Stock 14,362   14,362 I By Spouse
Stock Option (right to buy) $ 11.95               (13) 03/12/2023 Common Stock 20,000   20,000 I By Spouse
Restricted Stock Unit (3)               (5) 01/31/2017 Common Stock 2,500   2,500 I By Spouse
Stock Option (right to buy) $ 11.79               (14) 03/14/2024 Common Stock 25,000   25,000 I By Spouse
Restricted Stock Unit (RSU) (3)               (6) 04/13/2018 Common Stock 6,250   6,250 I By Spouse
Restricted Stock Unit (right to buy) (3)               (15)   (16) Common Stock 5,000   5,000 I By Spouse
Restricted Stock Unit (RSU) (3)               (17)   (16) Common Stock 15,000   15,000 I By Spouse
Stock Option (right to buy) $ 1.86               (18) 05/19/2025 Common Stock 37,500   37,500 I By Spouse
Restricted Stock Unit (RSU) (3)               (7) 06/18/2019 Common Stock 14,062   14,062 I By Spouse
Stock Option (right to buy) $ 0.85 03/14/2016   A   135,000     (8) 03/14/2026 Common Stock 135,000 $ 0 135,000 I By Spouse

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Cormack Scott Daniel
400-1001 W. BROADWAY
VANCOUVER, A1 V6H 4B1		   X     President and CEO  

Signatures

 Sandra Thomson as attorney-in-fact for Scott Cormack   03/16/2016
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
(2) Represents shares of common stock that have been sold by the issuer to satisfy the tax liability in connection with the settlement of RSUs.
(3) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.
(4) Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest on the later of: (i) each anniversary of January 1, 2012; and (ii) the first day thereafter during which the issuer's trading window is open.
(5) Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2013; and (ii) the first day thereafter during which the issuer's trading window is open.
(6) Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2014; and (ii) the first day thereafter during which the issuer's trading window is open.
(7) Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2015; and (ii) the first day thereafter during which the issuer's trading window is open.
(8) Pursuant to the terms of the options, 50% of the total shares underlying the option vest on the achievement of certain milestones, and 50% vest in monthly installments over 24 months commencing one month from achievement of one of the milestones. The options will lapse in full if achievement of one of the milestones is not met on or before December 31, 2016.
(9) The options were fully vested on May 12, 2010.
(10) The options were fully vested on May 26, 2011.
(11) The options were fully vested on January 3, 2015.
(12) The options were fully vested on January 1, 2016.
(13) The options vest in monthly installments over 48 months commencing one month from January 1, 2013.
(14) The options vest in monthly installments over 48 months commencing one month from January 1, 2014.
(15) Pursuant to the terms of the RSU, 100% of the total shares underlying the RSU vest on the later of (i) release of positive data from a clinical trial, and (ii) the first trading day thereafter on which the issuer's trading window is open.
(16) The RSUs expire 30 days from the date they vest.
(17) Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of June 12, 2014 and (ii) the first day thereafter during which the issuer's trading window is open.
(18) The options vest in monthly installments over 48 months commencing one month from January 1, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.